




# Beclometasone

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 25. Medicines acting on the respiratory tract > 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease

ATC codes: [R03BA01](#)

Indication	Asthma <span>ICD11 code: <a href="#">CA23</a></span>
INN	Beclometasone
Medicine type	Chemical agent
List type	Core
Formulations	Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate) ; 250 µg per dose (dipropionatae)
EML status history	First added in 1979 ( <a href="#">TRS 641</a> ) Changed in 1989 ( <a href="#">TRS 796</a> ) Changed in 1993 ( <a href="#">TRS 850</a> ) Changed in 1997 ( <a href="#">TRS 882</a> ) Removed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Beclometasone</a> 
DrugBank	<a href="#">Beclometasone (Beclomethasone dipropionate)</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended removal of the separate square box listing for beclometasone on the EML, and including beclometasone instead as one of the specified therapeutic alternatives in the square box listing for budesonide. The Committee recommended beclometasone, ciclesonide, flunisolide, fluticasone and mometasone be specified as therapeutic alternatives under the square box listing for budesonide on the EML and EMLc.

